-
11.发明申请公开(公告)号：US20220184228A1
公开(公告)日：2022-06-16
申请号：US17603268
申请日：2020-04-13
Applicant: Erlinda M. Gordon , Frederick L. Hall
Inventor： Erlinda M. Gordon , Frederick L. Hall
Abstract: Disclosed are methods for treating an individual with a chemotherapy-resistant primary and/or secondary malignancy that comprise administering a therapeutically effective amount of a tumor-targeted retrovector encoding a cytocidal dominant-negative Cyclin G1 construct, such as DeltaRex-G, to the individual. Also disclosed are methods in which DeltaRex-G, either alone or in conjunction with other cancer therapies and/or treatments, may be administered to ameliorate or eliminate the life-threatening effects of metastatic cancer.
-
公开(公告)号：US20210346520A1
公开(公告)日：2021-11-11
申请号：US17348736
申请日：2021-06-15
Applicant: Erlinda M. Gordon , Frederick L. Hall
Inventor： Erlinda M. Gordon , Frederick L. Hall
IPC: A61K48/00 , A61K38/18 , A61K45/06 , A61K31/704 , A61K31/4995 , A61K39/395 , A61P35/04
Abstract: The present disclosure teaches methods of treating a patient who has an advanced metastatic cancer, after the patient has the patient has failed at least one treatment regimen for the advanced metastatic cancer, by administering a plurality of infusions of a vector comprising a tumor signature-targeting peptide and a nucleic acid that encodes a dominant negative human cyclin G1 construct. One or more of the patient's treatment regimens may have included gemcitabine. The present disclosure also provides methods of treatment by further administering to the patient an additional therapeutic agent such as an immune-modulatory monoclonal antibody, a cytotoxic chemotherapeutic agent, an anti-angiogenesis agent, a selective tyrosine kinase inhibitor, or a monoclonal antibody directed against specific features of cells from the metastatic cancer.
-
13.发明申请公开(公告)号：US20210299276A1
公开(公告)日：2021-09-30
申请号：US17346089
申请日：2021-06-11
Applicant: Erlinda M. Gordon , Frederick L. Hall
Inventor： Erlinda M. Gordon , Frederick L. Hall
IPC: A61K48/00 , A61K31/45 , A61K31/496 , A61K31/167 , A61K31/4745 , A61K31/519 , A61K31/704 , A61K31/4995 , A61K39/395 , A61K9/00 , A61K31/357 , A61K31/05 , A61K31/19 , A61P35/00 , G01N33/50
Abstract: The present disclosure teaches methods of treating a patient having an advanced metastatic cancer by administering a plurality of infusions of a first therapeutic agent comprising a tumor-targeted gene vector that encodes a cytocidal inhibitor of the CCNG1 gene product and a second therapeutic agent that affects the activity of at least one additional molecular target along the CCNG1 pathway. The additional molecular target may be Mdm2, PP2A, p53, Rb, c-Myc, or a cyclin-dependent kinase. The present disclosure also provides methods of treatment by administering a plurality of infusions of a first therapeutic agent comprising a tumor-targeted gene vector that encodes a cytocidal inhibitor of the CCNG1 gene product and a second therapeutic agent such as an immune-modulatory monoclonal antibody, a cytotoxic chemotherapeutic agent, an anti-angiogenesis agent, a selective tyrosine kinase inhibitor, or a monoclonal antibody directed against specific features of cells from the metastatic cancer. Further, the disclosure provides methods of treating a palpable tumor, methods for evaluating the role of oncogenic drivers along the Cyclin G1 pathway in a tumor, and methods of treatment that use such evaluations/analyses to guide the management of the disease.
-
14.发明授权公开(公告)号：US09017659B2
公开(公告)日：2015-04-28
申请号：US12446976
申请日：2007-11-05
Applicant: Frederick L. Hall , Erlinda M. Gordon
Inventor： Frederick L. Hall , Erlinda M. Gordon
IPC: A61K48/00 , C12N15/63 , C07H21/04 , A61K31/7088 , A61K35/76 , A61K38/17 , A61K38/19 , A61K38/45 , A01K67/00
CPC classification number: A61K31/7088 , A61K35/76 , A61K38/1709 , A61K38/193 , A61K38/45 , A61K48/00 , C12N15/86 , C12N2740/13043 , C12N2740/13045 , C12N2810/85 , Y02A50/473 , A61K2300/00
Abstract: Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as cancer efficaciously with reduced adverse side effects.
Abstract translation: 提供用于致病性（寻疾）靶向基因递送的系统，包括具有极高滴度的病毒颗粒。 特别地，病毒颗粒被工程化以将治疗或诊断剂特异性递送到疾病部位，例如癌症转移部位。 还提供个性化的给药方案以有效地治疗诸如癌症的疾病，减少不良副作用。
-
公开(公告)号：US08828378B2
公开(公告)日：2014-09-09
申请号：US12724317
申请日：2010-03-15
Applicant: Erlinda M. Gordon , Frederick L. Hall
Inventor： Erlinda M. Gordon , Frederick L. Hall
CPC classification number: A61K47/4813 , A61K38/1709 , A61K38/191 , A61K38/193 , A61K38/2006 , A61K38/2013 , A61K38/2046 , A61K38/217 , A61K47/555 , A61K48/00 , C12N15/86 , C12N2740/13043 , C12N2740/13045 , C12N2810/857
Abstract: This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject. Also provided are a kit or drug delivery system comprising the compositions for use in the methods described.
Abstract translation: 本发明提供了治疗癌症的组合物和方法。 更具体地，本发明涉及包含细胞因子基因的靶向的逆转录病毒载体，其可以单独施用或与包含用于治疗受试者中的癌症的杀细胞基因的靶向逆转录病毒载体组合施用。 还提供了包含用于所述方法的组合物的试剂盒或药物递送系统。
-
Patent Agency Ranking
16.发明申请IDENTIFICATION OF A PLURIPOTENT PRE-MESENCHYMAL, PRE-HEMATOPOIETIC PROGENITOR CELL 审中-公开普鲁卡因前体细胞，前脑血管病原细胞的鉴定公开(公告)号：US20110052670A1
公开(公告)日：2011-03-03
申请号：US12828488
申请日：2010-07-01
Applicant: Frederick L. Hall , Erlinda M. Gordon
Inventor： Frederick L. Hall , Erlinda M. Gordon
CPC classification number: C12N5/0663 , A61K2035/124 , C12N5/0647 , C12N2500/42 , C12N2501/11 , C12N2501/125 , C12N2501/15 , C12N2501/23 , C12N2501/39 , C12N2510/00
Abstract: The present invention provides a molecular marker for the identification of pluripotent pre-mesenchymal, pre-hematopoietic stem cells. The invention further provides primitive progenitor cells identified by the molecular marker. Such cells have the potential to differentiate into both mesenchymal and hematopoietic phenotypes, as determined by a proliferative response to inductive growth factors and cytokines, and by their morphologic and cytochemical features.
Abstract translation: 本发明提供了用于鉴定多能前间充质干细胞的分子标记物。 本发明还提供了由分子标记鉴定的原始祖细胞。 这样的细胞具有分化成间充质和造血表型的潜力，如通过诱导生长因子和细胞因子的增殖反应以及其形态和细胞化学特征所确定的。
-
公开(公告)号：US20100233127A1
公开(公告)日：2010-09-16
申请号：US12724317
申请日：2010-03-15
Applicant: Erlinda M. Gordon , Frederick L. Hall
Inventor： Erlinda M. Gordon , Frederick L. Hall
CPC classification number: A61K47/4813 , A61K38/1709 , A61K38/191 , A61K38/193 , A61K38/2006 , A61K38/2013 , A61K38/2046 , A61K38/217 , A61K47/555 , A61K48/00 , C12N15/86 , C12N2740/13043 , C12N2740/13045 , C12N2810/857
Abstract: This invention provides compositions and methods for treating cancer. More specifically this invention is directed to a targeted retroviral vector comprising a cytokine gene that can be administered either alone or in combination with a targeted retroviral vector comprising a cytocidal gene for treating cancer in a subject. Also provided are a kit or drug delivery system comprising the compositions for use in the methods described.
Abstract translation: 本发明提供了治疗癌症的组合物和方法。 更具体地，本发明涉及包含细胞因子基因的靶向的逆转录病毒载体，其可以单独施用或与包含用于治疗受试者中的癌症的杀细胞基因的靶向逆转录病毒载体组合施用。 还提供了包含用于所述方法的组合物的试剂盒或药物递送系统。
-
18.发明申请公开(公告)号：US20100016413A1
公开(公告)日：2010-01-21
申请号：US12446976
申请日：2007-11-05
Applicant: Frederick L. Hall , John P. Levy , Rebecca A. Reed , Erlinda M. Gordon
Inventor： Frederick L. Hall , John P. Levy , Rebecca A. Reed , Erlinda M. Gordon
IPC: A61K31/7088 , C12N15/63 , A61P35/00
CPC classification number: A61K31/7088 , A61K35/76 , A61K38/1709 , A61K38/193 , A61K38/45 , A61K48/00 , C12N15/86 , C12N2740/13043 , C12N2740/13045 , C12N2810/85 , Y02A50/473 , A61K2300/00
Abstract: Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as cancer efficaciously with reduced adverse side effects.
Abstract translation: 提供用于致病性（寻疾）靶向基因递送的系统，包括具有极高滴度的病毒颗粒。 特别地，病毒颗粒被工程化以将治疗或诊断剂特异性递送到疾病部位，例如癌症转移部位。 还提供个性化的给药方案以有效地治疗诸如癌症的疾病，减少不良副作用。
-
19.发明授权Matrix-targeted fusion polypeptides for tissue regeneration and wound healing 失效用于组织再生和伤口愈合的基质靶向融合多肽公开(公告)号：US07459541B2
公开(公告)日：2008-12-02
申请号：US10733852
申请日：2003-12-10
Applicant: Frederick L. Hall , Erlinda M. Gordon , Robert W. Beart , Marcel Nimni
Inventor： Frederick L. Hall , Erlinda M. Gordon , Robert W. Beart , Marcel Nimni
IPC: C07K14/475 , C07K14/48 , C07K14/62 , C07K14/71
CPC classification number: C12N5/0679 , A61K35/12 , A61K38/00 , A61K48/00 , C07K14/485 , C07K14/755 , C07K2319/00
Abstract: The present invention relates to compositions and methods for promoting tissue repair and regeneration. The invention provides a fusion polypeptide useful for targeting tissues for regeneration and methods of use therefore.
Abstract translation: 本发明涉及用于促进组织修复和再生的组合物和方法。 本发明提供了可用于靶向用于再生的组织的融合多肽和因此使用的方法。
-
公开(公告)号：US06955898B2
公开(公告)日：2005-10-18
申请号：US10125332
申请日：2002-04-17
Applicant: Frederick L. Hall , Erlinda M. Gordon , Vaughn A. Starnes , W. French Anderson
Inventor： Frederick L. Hall , Erlinda M. Gordon , Vaughn A. Starnes , W. French Anderson
IPC: C12N15/09 , A01K67/027 , A61K38/00 , A61K38/19 , A61K38/27 , A61K38/43 , A61K39/395 , A61K47/48 , A61K48/00 , A61L27/00 , A61P1/00 , A61P1/04 , A61P3/10 , A61P9/00 , A61P19/02 , A61P29/00 , A61P31/00 , A61P35/00 , C07K7/06 , C07K14/52 , C07K14/755 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/62 , C12P21/02 , C12Q1/02 , C12P21/06
CPC classification number: A01K67/0271 , A61K38/00 , A61K38/1866 , A61K48/00 , C07K14/755 , C07K2319/00 , C07K2319/21 , C07K2319/70 , C07K2319/75 , C12N15/62 , C12N2799/023 , A61K2300/00
Abstract: The present invention provides new compositions and methods to induce therapeutic angiogenesis locally utilizing a collagen binding domain to target an angiogenesis modulating agents. Fusion polypeptides containing a collagen binding domain linked to an angiogenesis modulating agent are provided, as are nucleic acid sequences encoding the fusion polypeptides. Also included are methods for locally altering circulation by administering a fusion polypeptide consisting of a collagen binding domain linked to an angiogenesis modulating agent, or by administering a nucleic acid sequences encoding the fusion polypeptide. Tissue grafts in which isolated tissue is treated with a fusion polypeptide consisting of a collagen binding domain linked to an angiogenesis modulating agent, or with a nucleic acid sequences encoding the fusion polypeptide are also provided, as are methods of making the grafts.
Abstract translation: 本发明提供了新的组合物和方法，其在局部利用胶原结合结构域靶向血管生成调节剂来诱导治疗性血管生成。 提供了与血管生成调节剂连接的含有胶原结合结构域的融合多肽，以及编码融合多肽的核酸序列。 还包括通过施用由与血管生成调节剂连接的胶原结合结构域组成的融合多肽或通过施用编码融合多肽的核酸序列来局部改变循环的方法。 还提供了组织移植物，其中分离的组织用由与血管生成调节剂连接的胶原结合结构域或与编码融合多肽的核酸序列组成的融合多肽处理，以及制备移植物的方法。
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.039 seconds)
